Blepharitis Treatment Market

Blepharitis Treatment Market - Size, Share,
Growth, Outlook, and Opportunity Analysis,
2018-2026
Blepharitis is a chronic condition that causes inflammation of the eyelids. Blepharitis usually affects
the part of eyelid where eyelashes grow and occurs when tiny oil glands near this area are clogged,
in turn causing irritation and redness of the eyes. Symptoms of blepharitis include high sensitivity to
light, loss of eyelashes, watery eyes, burning sensation in the eyes, greasy eyelids, itchy eyes, red
and swollen eyes, flaking of skin around the eyes, crusted eyelashes after waking up, more frequent
blinking, abnormal growth of eyelashes, and stinging sensation in the eyes. Blepharitis causes
seborrheic dermatitis, which is dandruff of the eyebrows and scalp, bacterial infection, clogged oil
glands, malfunctioning of oil glands, rosacea. It also causes allergic reactions to eye medications,
contact lens solutions or eye make-up and eyelash lice or mites.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1761
The blepharitis treatment market is expected to witness significant grow due to growing prevalence of
ophthalmic disorders among the geriatric population. According to a survey conducted by American
Academy of Ophthalmology in 2014, blepharitis usually affects people above the age of 50 years. It
also states that blepharitis is observed in 37% male ophthalmic patients and 47% in female
ophthalmic patients. Blepharitis market is also expected to grow due to increasing number of drugs in
the pipeline. For instance, ISV-305 sponsored by InSite Vision is in phase 3 clinical trials, ISV-305
treats patients with early symptoms of blepharitis. Furthermore, new product launches and mergers
and acquisitions over the recent past also contributes to market growth. For instance, in 2015,
BlephEx, a Franklin-based company launched Rysurg. It is used to clean eyelids and also maintains
hygiene. According to a study conducted by American Academy of Ophthalmology in 2015 around
50% of ophthalmic patients suffer from symptoms of blepharitis and dry eyes. Constant use of this
device helps prevent recurrence of blephairis and the treatment is pain-free. In 2013, Shire Plc,
purchased Californian Ophthalmic Company SARcode Bioscience to add new drug lifitegrast to
Shire’s specialist drug portfolio. Lifitegrast was approved by the FDA for the treatment of signs and
symptoms of dry eye and blepharitis in 2016.
North America Blepharitis treatment market is expected to hold dominant position due to
increasing geriatric population, launch of new products, and increasing number of ophthalmic
patients in the region. According to a survey conducted in the U.S., by Population Reference
Bureau in 2016, states that the aging population increased by 24% as compared to 15% in 2014.
Europe is expected to witness rapid growth due to new product launches of blepharitis drugs in
the region. For instance, in 2017, Scope Ophthalmic launched Moist Heat Mask, a device that
helps in the treatment of blepharitis by loosening the oil present in Meibomian glands and
allowing it to flow more freely. It helps to soften eye lash debris, prevent the evaporation of
natural tear film, restores moisture to the eye and also the surrounding area, as well as improves
tear film lipid quality. In 2015, MiBo Medical Group, a U.S.-based company, launched MibO
Thermoflo. This device helps in the treatment of blepharitis and dry eyes and is required to be
gently massaged on the margins of the eyelids for a minimum of 12 minutes. In 2015, MiBo
Medical Group launched Lid Pro, a device that is used to treat anterior Blepharitis. The region of
Asia Pacific is expected to witness significant growth due to increasing prevalence of blepharitis.
According to a study conducted by Journal of Clinical and Experimental Ophthalmology in 2016,
signs and symptoms of blepharitis increased by 32% among the geriatric population as
compared to 2014.
Report includes chapters which deeply display the following deliverable about industry :
• Blepharitis Treatment Market Research Objective and Assumption
• Blepharitis Treatment Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Blepharitis Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value
Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Blepharitis Treatment Market, By Regions
• Blepharitis Treatment Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Blepharitis Treatment Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Blepharitis Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Blepharitis Treatment Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Blepharitis Treatment Market Key Players:Key players operating in the Blepharitis treatment market include Scope Ophthalmic
Ltd, NovaBay Pharmaceuticals Inc, Thea Pharmaceuticals Ltd, Perrigo Laboratories,
InSite Vision Incorporated, Merck & Co, and Novartis AG
Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-toanalyst/1761
Blepharitis Treatment Market Taxonomy:The global Blepharitis treatment market is segmented based on disease type, treatment type,
distribution channel, and region.
By Disease Type:• Posterior Blepharitis
• Anterior Blepharitis
• Mixed Blepharitis
By Treatment Type:•
•
•
•
•
•
•
Antibiotic Therapy
Topical Corticosteroids
Topical Antibodies
Oral Antibodies
Ointments
Eye Cleansers
Others
By Distribution Channel:• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region:-
•
•
•
•
•
•
North America
Europe
Latin America
Asia-Pacific
Middle East
Africa
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Download Report